By: ICN Bureau
Last updated : August 28, 2025 9:31 am
On international chemicals, Sasol achieved adjusted EBITDA improved by more than US$120 million (US$411million for FY25).
Sasol Limited announced its financial results for the year ended 30 June 2025, reflecting significant progress in executing its strategy and commitments outlined at its Capital Markets Day (CMD) in May 2025.
Despite a challenging macroeconomic and operating environment, Sasol achieved 75 per cent higher free cash flow compared to the previous year, driven by strong cost discipline and prudent capital management.
“FY25 has been a pivotal year for Sasol as we celebrate our 75th anniversary, and pursue our future with renewed purpose,” said Simon Baloyi, President and Chief Executive Officer.
“At CMD, we outlined clear FY28 objectives: restore reliability and competitiveness in our Southern Africa operations, enhance margins in our International Chemicals business, and advance growth and transformation initiatives in a value-accretive manner. We also committed to prioritizing deleveraging through disciplined capital allocation and free cash flow generation. Today’s results demonstrate tangible progress toward these commitments.” “FY25 marks the beginning of a disciplined, focused journey toward a resilient, competitive, and sustainable Sasol. We are running the marathon we committed to at CMD — with pace, discipline, and unwavering focus,” added Baloyi.
He added: “Our Southern Africa operations are on track with our initiatives towards improved reliability and cost efficiency. Profitability in International Chemicals has improved, despite the prolonged downturn in the chemical market. Further, we are continuing to progress our emission reduction roadmap at a significantly lower capital cost than originally anticipated. We are running the marathon we spoke about at CMD — with discipline, pace, and unwavering focus.”
On international chemicals, Sasol achieved adjusted EBITDA improved by more than US$120 million (US$411million for FY25). Adjusted EBITDA margins increased from 6% to 9%, despite the prolonged downturn in the chemical market – evidence of our reset initiatives and supported by more favourable pricing. The business will build on this momentum into FY26, and ultimately ramping up to achieve the FY28 targets.